November 9, 2017 / 10:03 PM / a year ago

BRIEF-IntelGenx submits Montelukast VersaFilm(tm) clinical trial application with Health Canada

1 Min Read

Nov 9 (Reuters) - IntelGenx Technologies Corp

* IntelGenx submits Montelukast VersaFilm(tm) clinical trial application with Health Canada

* IntelGenx - ‍submitted CTA to Health Canada for approval to initiate its Phase 2a POC study with Montelukast in mild to moderate alzheimer’s disease Source text for Eikon: Further company coverage:

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below